The strong sequential revenue growth and expanding commercial footprint are positive signals for adoption trajectory. However, without absolute revenue or margin figures, the magnitude of improvement is unclear. Monitor the upcoming 10-Q for actual dollar amounts and cost trends to assess path to profitability.
Price Chart
Executive Summary
Microbot Medical filed its Q2 2026 10-Q and highlighted revenue growth of more than 100% sequentially, driven by the Full Market Release of the LIBERTY Endovascular Robotic System. The company added new health systems, expanded to 8 sales territories, secured a federal healthcare agreement with Lovell Government Services, and obtained marketing clearance in Israel. No absolute dollar figures were disclosed, but the operational momentum is clearly positive.
Key Facts
- Total revenue increased more than 100% compared to Q1 2026
- New health systems adopted LIBERTY in Massachusetts, North Carolina, Michigan, and Pennsylvania
- Sales footprint expanded from 4 to 8 territories, on track for 12 by year-end
- Entered agreement with Lovell Government Services to serve >2,000 federal healthcare facilities
- Israel granted marketing clearance for LIBERTY System (first jurisdiction outside U.S.)
- Entered agreement with Sanmina for a second manufacturing site to expand production capacity
- Cost of revenue increased QoQ but company expects substantial reduction going forward
Financial Impact
Revenue more than doubled sequentially (Q2 vs Q1 2026); absolute figures not disclosed. Cost of revenue increased but expected to decline with completion of Limited Market Release costs and cost reduction initiatives.
Risk Factors
- Cost of revenue increased in Q2 and may pressure gross margins near term
- Commercial-stage company with limited operating history; adoption ramp may be lumpy
- No absolute revenue or EPS figures provided, making valuation assessment difficult
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037031 |
| Exhibit: ex99-1.htm | 0001493152-26-037031 |
| Document: 0001493152-26-037031-index-headers.html | 0001493152-26-037031 |
| Document: 0001493152-26-037031-index.html | 0001493152-26-037031 |
| Document: 0001493152-26-037031.txt | 0001493152-26-037031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.9799 | awaiting T+1 | — | $0.9700 (−1.01%) |
Oct 20, 2026 6d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9700 (+2.37%) |
Oct 6, 2026 20d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9700 (−9.35%) |
Oct 6, 2026 20d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9700 (−9.35%) |
Sep 28, 2026 28d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9700 (−22.40%) |
Aug 11, 2026 10w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9700 (−42.26%) |
Jul 21, 2026 13w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9700 (−46.11%) |
Jul 7, 2026 15w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9700 (−48.95%) |
Jun 30, 2026 16w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9700 (−50.26%) |
Jun 16, 2026 18w ago | 8-K | $1.82 $1.88 | ▲ +3.30% | ▲ +4.55% | $0.9700 (−46.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers